Table 3.
Alert | Suggestion | A | R | U1 | U2 | |
---|---|---|---|---|---|---|
H | Anesthesia postoperative nausea and vomiting | Scope of roles should include fellow. | 4.8 ± 0.5 | 4.8 ± 0.5 | 4.8 ± 0.5 | 4.8 ± 0.5 |
H | Immunocompromised, live virus vaccine | Pregnant patients. | 3.0 ± 1.0 | 4.8 ± 0.5 | 4.4 ± 0.9 | 4.8 ± 0.5 |
A | Immunocompromised, live virus vaccine | Some examples of additional medications or treatments that may have immunosuppressive effects include certain cancer treatments, such as chemotherapy or radiation therapy, as well as certain medications used to treat autoimmune disorders, such as rituximab or infliximab. | 2.4 ± 1.1 | 4.8 ± 0.5 | 4.8 ± 0.5 | 4.6 ± 0.6 |
A | Immunocompromised, live virus vaccine | Exclude: Patient is currently receiving radiation or chemotherapy treatment. | 2.6 ± 1.5 | 4.4 ± 0.6 | 3.8 ± 1.6 | 4.5 ± 0.6 |
H | Immunocompromised, live virus vaccine | Add an active chemotherapy criterion. | 2.4 ± 0.9 | 4.8 ± 0.5 | 4.8 ± 0.5 | 4.4 ± 0.6 |
A | Immunocompromised, live virus vaccine | Add biologic agents, such as adalimumab, etanerfigut [sic]a, and golimumab, which are used to treat autoimmune disorders. | 2.2 ± 1.1 | 4.8 ± 0.5 | 4.6 ± 0.6 | 4.4 ± 0.6 |
A | Immunocompromised, live virus vaccine | Exclude: Patients who have recently undergone bone marrow transplant or solid organ transplant. | 2.2 ± 1.3 | 4.6 ± 0.6 | 4.0 ± 1.7 | 4.3 ± 0.5 |
H | Immunocompromised, live virus vaccine | Make the list of immunosuppression medications more complete. | 2.4 ± 1.1 | 4.6 ± 0.6 | 4.6 ± 0.6 | 4.2 ± 0.8 |
H | IP allergy documentation | Exclude NICU and newborn departments. | 3.4 ± 1.3 | 4.2 ± 0.5 | 4.4 ± 0.6 | 4.2 ± 0.5 |
A | Pediatrics bronchiolitis patients with inappropriate order | Exclude patients with other respiratory conditions, such as pneumonia or asthma, that may require chest radiography or albuterol treatment. | 2.6 ± 0.9 | 4.6 ± 0.6 | 4.8 ± 0.5 | 4.0 ± 1.2 |
A | Immunocompromised, live virus vaccine | Add medications used to treat transplant rejection, such as basiliximab, daclizumab, and muromonab-CD3. | 2.4 ± 1.1 | 4.4 ± 0.6 | 4.6 ± 0.6 | 4.0 ± 1.2 |
H | Anesthesia postoperative nausea and vomiting | Currently history of PONV looks to problem list, but it should also look to the last anesthesia preop evaluation. | 3.4 ± 0.9 | 4.8 ± 0.5 | 4.4 ± 0.9 | 4.0 ± 1.0 |
A | Immunocompromised, live virus vaccine | Exclude: Currently receiving immunosuppressive therapy or who have recently completed such therapy. | 1.8 ± 1.1 | 4.2 ± 0.5 | 3.6 ± 1.5 | 4.0 ± 0.8 |
H | Artificial tears frequency >6/day | Add additional eye drops. | 2.4 ± 0.9 | 4.2 ± 0.5 | 4.4 ± 0.6 | 4.0 ± 0.7 |
H | Pediatrics bronchiolitis patients with inappropriate order | Add a 3rd OR statement if the ED bronchiolitis panel was used during this encounter. | 3.2 ± 1.6 | 3.8 ± 1.6 | 3.8 ± 1.6 | 3.8 ± 1.6 |
H | Artificial tears frequency >6/day | Restrict inpatient options to only formulary. | 3.2 ± 0.8 | 3.8 ± 1.1 | 4.0 ± 1.2 | 3.8 ± 1.1 |
H | Artificial tears frequency >6/day | Add inpatient orders. | 3.6 ± 0.9 | 3.8 ± 1.1 | 3.8 ± 1.1 | 3.8 ± 1.1 |
A | Pediatrics bronchiolitis patients with inappropriate order | Exclude patients who are receiving palliative care or end-of-life care, as these patients may require chest radiography or albuterol treatment for symptom management. | 3.2 ± 1.6 | 3.6 ± 1.7 | 4.4 ± 0.9 | 3.6 ± 1.7 |
H | Immunocompromised, live virus vaccine | Add patients with transplant on problem list. | 2.6 ± 1.3 | 4.6 ± 0.6 | 4.6 ± 0.6 | 3.6 ± 1.5 |
A | Anesthesia postoperative nausea and vomiting | Patients who have had previous PONV episodes, as they may be at higher risk for developing PONV again. | 2.0 ± 1.0 | 4.6 ± 0.6 | 4.6 ± 0.6 | 3.6 ± 1.1 |
Etanerfigut is either a misspelling, which is hard to imagine from a computer, or a nonexistent medication hallucinated by ChatGPT.
NICU: neonatal intensive care unit; PONV: postoperative nausea and vomiting; ED: emergency department; CD3: cluster of differentiation 3; H: human-generated suggestions; A: AI-generated suggestions.